Efficacy and safety of Ketoprofen Gel treatment in patients with low back pain





low back pain, topical form, ketoprofen gel


Background. The purpose was to study the effectiveness and safety of Ketoprofen gel (Fastum gel) therapy in patients with low back pain (LBP) caused by degenerative-dystrophic changes of the spine. Materials and methods. 24 males and females aged 50-69 years with LBP lasting over 14 days were examined, with a further division into two groups. Group I – 12 patients received thin ketoprofen applications on the lumbar region 2 times a day for 10 days. Group II – 12 patients who received thin applications of Vaseline on the same area 2 times a day for 10 days. Patients used the study drugs as a monotherapy. Examination was performed before the treatment initiation, after 10 and 20 days of treatment. Results. Patients receiving ketoprofen applications had a significantly reduced pain intensity registered by all four components of VAS and the Roland-Morris questionnaire. At the same time, the functional capacity by Schober (t = 3.54, p = 0.005) and Tomayer (t = 3.08, p = 0.01) tests was significantly improved. The quality of life according to the EuroQul-5D scale in patients who used the topical ketoprofen significantly increased by 45 % (t = 4.19, p = 0.002), and life expectancy according to the Oswestry questionnaire by 39.3 % after 10 days of treatment (t = 3.9, p = 0.002). 75 % of patients from the main group and 33.3 % from the compa­rison group assessed the effectiveness of treatment as high according to the Likert index. Neither group reported localized nor systemic side effects. Conclusions. Monotherapy of ketoprofen gel significantly reduced the intensity of pain and improved the functional capacity of patients with LBP. The absence of side effects during treatment indicates its high safety profile for patients.


Download data is not yet available.


Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task Force on research standards for chronic low back pain. Phys Ther. 2015 Feb;95(2):e1-e18. https://doi.org/10.2522/ptj.2015.95.2.e1.

Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 9;391(10137):2356-2367. https://doi.org/10.1016/s0140-6736(18)30480-x.

Bozhenko NL. Backache: some aspects of diagnostics and treatment. Liky Ukrai'ny. 2015;(190):58-65. https://doi.org/10.37987/1997-9894.2015.4(190).207916. (in Ukrainian).

Kopchak OO. The problem of lower back pain taking into account evidence-based medicine data. Mezhdunarodnyi Nevrologicheskii Zhurnal. 2020;16(3):41-49. https://doi.org/10.22141/2224-0713.16.3.2020.202769. (in Ukrainian).

Katić M, Svab I. Family Medicine. Zagreb: Medicinska naklada; 2017. 31-39 pp.

McMahon SB, Dargan P, Lanas A, Wiffen P. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty. Curr Med Res Opin. 2021 Feb;37(2):287-292. https://doi.org/10.1080/03007995.2020.1847718.

Verhagen AP, Downie A, Popal N, Maher C, Koes BW. Red flags presented in current low back pain guidelines: a review. Eur Spine J. 2016 Sep;25(9):2788-802. https://doi.org/10.1007/s00586-016-4684-0.

Urits I, Burshtein A, Sharma M, et al. Low Back Pain, a Comprehensive Review: Pathophysiology, Diagnosis, and Treatment. Curr Pain Headache Rep. 2019 Mar 11;23(3):23. https://doi.org/10.1007/s11916-019-0757-1.

Back L, Urits I, Burshtein A, Sharma M, et al. Other Pain (A. Kaye аnd N. Vadivelu, Section Editors) and Treatment 2019:1-10. https://doi.org/10.1007/s11916-019-0757-1.

Witenko C, Moorman-Li R, Motycka C, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014 Jun;39(6):427-435.

Stein H, Braun Y, Volpin G. Low back pain. Orthopedics. 2006 Mar;29(3):229-231. https://doi.org/10.3928/01477447-20060301-08.

Last AR, Hulbert K. Chronic low back pain: Evaluation and management. South African Fam Pract. 2010;52(3):184-192. https://doi.org/10.1080/20786204.2010.10873969.

Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. https://doi.org/10.1016/j.ejpain.2005.06.009.

Rafanan BS Jr, Valdecañas BF, Lim BP, et al. Consensus recommendations for managing osteoarthritic pain with topical NSAIDs in Asia-Pacific. Pain Manag. 2018 Mar;8(2):115-128. https://doi.org/10.2217/pmt-2017-0047.

Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016 Apr 22;4(4):CD007400. https://doi.org/10.1002/14651858.cd007400.pub3.

Komatsu T, Sakurada T. Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci. 2012 Dec 18;47(5):890-895. https://doi.org/10.1016/j.ejps.2012.08.016.




How to Cite

Povoroznyuk, V., Musiienko, A., Zaverukha, N., & Tkachuk , A. (2021). Efficacy and safety of Ketoprofen Gel treatment in patients with low back pain. PAIN, JOINTS, SPINE, 11(1), 28–34. https://doi.org/10.22141/2224-1507.11.1.2021.226906



Original Researches

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>